DELTA-DOME
Clinical safety rating: caution
Comprehensive clinical and safety monograph for DELTA-DOME (DELTA-DOME).
Delta-dome agents, likely referring to delta-9-tetrahydrocannabinol (THC) analogs or synthetic cannabinoids, act as partial agonists at cannabinoid receptors CB1 and CB2. CB1 receptors are primarily located in the central nervous system, modulating neurotransmitter release, while CB2 receptors are mainly in immune cells, influencing cytokine release and immune response.
| Metabolism | Hepatic metabolism primarily via cytochrome P450 enzymes, notably CYP2C9 and CYP3A4, with minor contributions from CYP2C19. Active metabolites (e.g., 11-hydroxy-THC) are formed. |
| Excretion | Primarily hepatic metabolism with renal excretion of inactive metabolites (approximately 80% in urine, 20% in feces as bile salts). Less than 1% excreted unchanged. |
| Half-life | Terminal elimination half-life is 2-4 hours in adults, prolonged to 4-8 hours in hepatic impairment; correlates with duration of pulmonary effects. |
| Protein binding | Approximately 90% bound to glucocorticoid-binding globulin (transcortin) and albumin. |
| Volume of Distribution | 0.5-1.0 L/kg, indicating extensive tissue distribution. |
| Bioavailability | Inhalation: ~15-30% pulmonary deposition; Intramuscular: ~80-100%; Oral: not applicable due to extensive first-pass metabolism. |
| Onset of Action | Inhalation: 3-5 minutes; Intramuscular: 2-3 hours; Intravenous: 15-30 minutes. |
| Duration of Action | Inhalation: 4-6 hours; Intramuscular: 6-8 hours; Intravenous: 4-6 hours; duration increased in hepatic disease. |
Intramuscular or subcutaneous injection of 0.5 to 1 mL (5-10 mg/mL) every 4 to 6 hours as needed.
| Dosage form | TABLET |
| Renal impairment | GFR 30-50 mL/min: administer 75% of normal dose every 6 hours; GFR 15-29 mL/min: administer 50% of normal dose every 8 hours; GFR <15 mL/min: administer 50% of normal dose every 12 hours. |
| Liver impairment | Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 25%; Child-Pugh Class C: reduce dose by 50% and monitor closely. |
| Pediatric use | Children 2-12 years: 0.1-0.2 mg/kg/dose intramuscularly every 4-6 hours; maximum 10 mg/dose. |
| Geriatric use | Initiate at lower end of dosing range (e.g., 2.5-5 mg) due to increased sensitivity and risk of adverse effects; monitor renal function and adjust accordingly. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for DELTA-DOME (DELTA-DOME).
| Breastfeeding | Contraindicated during breastfeeding. M/P ratio not established; drug excreted in human milk and may cause adverse effects in nursing infants. |
| Teratogenic Risk | Pregnancy category X. Contraindicated in pregnancy due to association with severe fetal abnormalities including craniofacial defects, cardiovascular malformations, and neural tube defects. Risk is highest during first trimester exposure. |
| Fetal Monitoring |
■ FDA Black Box Warning
No specific FDA boxed warning is identified for delta-dome agents. However, cannabinoids carry risks of dependence, withdrawal, and psychiatric adverse effects.
| Serious Effects |
Hypersensitivity to cannabinoids, history of psychosis or schizophrenia, severe hepatic impairment, pregnancy (category C), and breastfeeding.
| Precautions | Central nervous system depression (sedation, dizziness), cognitive impairment, increased risk of psychiatric reactions (anxiety, paranoia, psychosis), cardiovascular effects (tachycardia, hypotension), driving impairment, and potential for abuse and dependence. |
Loading safety data…
| Perform pregnancy test prior to initiation and monthly during therapy. Monitor for signs of fetal distress if accidental exposure occurs. No specific fetal monitoring indicated if drug discontinued. |
| Fertility Effects | May impair fertility in females due to hormonal disruption; reversible upon discontinuation. No data on male fertility effects. |